Pitcairn Co. Reduces Position in Haleon PLC Sponsored ADR $HLN

Pitcairn Co. decreased its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 36.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 178,503 shares of the company’s stock after selling 100,878 shares during the period. Pitcairn Co.’s holdings in Haleon were worth $1,601,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Bank of America Corp DE grew its position in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after purchasing an additional 3,207,986 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Haleon by 3,031.5% in the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after purchasing an additional 5,212,711 shares during the last quarter. Optiver Holding B.V. purchased a new position in Haleon in the 3rd quarter worth about $45,593,000. Finally, Raymond James Financial Inc. increased its stake in Haleon by 0.7% in the 2nd quarter. Raymond James Financial Inc. now owns 4,315,180 shares of the company’s stock worth $44,748,000 after buying an additional 29,287 shares during the period. 6.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on HLN shares. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

NYSE HLN opened at $10.28 on Friday. The company has a market cap of $45.78 billion, a PE ratio of 26.36 and a beta of 0.18. The firm’s 50 day moving average price is $10.50 and its 200-day moving average price is $9.84. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42.

Haleon Announces Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be given a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a yield of 251.0%. Haleon’s dividend payout ratio (DPR) is presently 28.21%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.